Core Viewpoint - The company has entered into a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Company for approximately HKD 40 million to HKD 45 million, which is seen as a strategic investment to enhance its participation in the healthcare sector and create long-term value [1] Group 1: Acquisition Details - The acquisition involves China Gene Engineering Company, which is registered in Hong Kong and holds approximately 67.68% of Shanghai Huaxin Biological High-tech Co., Ltd [1] - The total consideration for the acquisition is estimated to be between HKD 40 million and HKD 45 million [1] Group 2: Business Synergy - China Gene Group is primarily engaged in the internal research and development, manufacturing, and sales of biopharmaceutical products in China [1] - The acquisition aligns with the company's existing businesses in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services [1] Group 3: Strategic Importance - The board views the acquisition as an excellent opportunity to increase the company's involvement in the operations of China Gene Group [1] - This strategic investment is expected to generate potential long-term value and facilitate business development in the promising healthcare industry [1]